BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2024
0mins
Source: Newsfilter
BetterLife Pharma's Cardiac Safety Study: BetterLife Pharma Inc. has completed a cardiac safety study for its non-hallucinogenic drug BETR-001, showing minimal impact on the hERG channel, which is crucial for heart function, indicating a clean cardiac safety profile.
Focus on Neuro-Psychiatric Treatments: The company is developing BETR-001 and BETR-002 to treat various neuro-psychiatric disorders, with BETR-001 being unique as it is unregulated and can be self-administered, while BETR-002 is based on honokiol for anxiety-related disorders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
